Patient guide · Reviewed May 2026
Early Detection of Liver Disease in Australia — Why It Matters and Who Should Be Tested
Liver disease is one of the most underdiagnosed serious health conditions in Australia — not because it is rare, but because it is almost always silent in its early stages. By the time symptoms appear, the disease has often progressed beyond the point where intervention is most effective.
Early detection changes this. For the 7.8 million Australians estimated to have fatty liver disease (MASLD), identifying the condition before significant fibrosis has developed opens a window for treatment that simply does not exist once cirrhosis sets in.
Published 2026-05-31 · Clinically reviewed 2026-05-31
Patient guide · Reviewed May 2026
The Silent Nature of Liver Disease
Most liver diseases, including MASLD, produce no symptoms in their early stages. A person can have 30–40% of their liver affected by fat, with developing…
Most liver diseases, including MASLD, produce no symptoms in their early stages. A person can have 30–40% of their liver affected by fat, with developing inflammation and early fibrosis, and feel entirely normal. No pain. No fatigue beyond what might be attributed to a busy life. No visible signs.
MASLD is highly prevalent in Western countries and is often asymptomatic. Fatigue is the most common symptom, but advanced stages can lead to cirrhosis, hepatocellular carcinoma, and liver failure.
The critical point: by the time symptoms appear — jaundice, swollen abdomen, easy bruising — the liver disease has typically advanced to cirrhosis or beyond. At this stage, treatment options are significantly more limited and outcomes are substantially worse.
Why Early Detection Matters More Than Ever in 2026
Early detection of liver disease has always been clinically useful. In 2026, it has become genuinely actionable in a way that was not previously possible.
The treatment landscape has changed. In April 2026, the TGA provisionally approved Wegovy (semaglutide 2.4mg) for the treatment of adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (stages F2–F3). This is a disease-modifying treatment that can halt and in many cases reverse established liver fibrosis — but only in patients who have not yet progressed to cirrhosis (F4).
This creates a genuine window: patients with F2–F3 fibrosis who are identified early can be treated before they progress to cirrhosis. Patients who are not identified until F4 cannot receive this treatment. Early detection is the difference between being in the treatable group and being in the group that has missed the window.
The patient cohort is growing rapidly. 500,000 Australians are now on GLP-1 medications. The MJA September 2025 consensus statement recommends MASLD assessment for all GLP-1 patients with metabolic risk factors. This creates a new clinical imperative for systematic early detection in primary care.
Patient guide · Reviewed May 2026
Who Is at Risk — and Should Be Tested
The following groups have significantly elevated risk of MASLD and should be systematically screened:
The following groups have significantly elevated risk of MASLD and should be systematically screened:
Type 2 diabetes: MASLD affects 65–75% of people with type 2 diabetes. It is the most common chronic liver disease in this population. If you have type 2 diabetes and have never had your liver health assessed, ask your GP for a FIB-4 calculation at your next appointment.
Obesity (BMI above 30): MASLD affects 60–80% of people with obesity. Combined with metabolic syndrome, the prevalence approaches 90%.
GLP-1 medication users: Australians on Ozempic, Wegovy, or Mounjaro who have metabolic risk factors meet the MJA 2025 guidelines criteria for MASLD screening.
Elevated liver enzymes: ALT, AST, or GGT above the normal range on any blood test without a clear explanation warrants liver assessment.
Metabolic syndrome: The combination of central obesity, high blood pressure, high triglycerides, low HDL cholesterol, and impaired fasting glucose creates a high-risk metabolic environment for MASLD.
Family history of liver disease: First-degree relatives of people with cirrhosis, liver cancer, or liver failure have elevated genetic risk for MASLD progression.
The Early Detection Pathway — What It Looks Like in Practice
Early detection does not require specialist referral or expensive testing as a first step. The recommended Australian pathway starts in the GP's surgery:
- Step 1 — FIB-4 score from routine bloods: If you have had a blood test including ALT, AST, and platelets, your GP can calculate your FIB-4 score immediately. This costs nothing extra and takes seconds.
- FIB-4 below 1.3 is reassuring — low risk of significant fibrosis. Repeat in 3 years.
- FIB-4 between 1.3 and 2.67 is indeterminate. This is where most at-risk patients land — and this is the group where early detection with elastography makes the biggest difference.
- FIB-4 above 2.67 is high risk. Specialist referral recommended.
- Step 2 — Liver elastography for indeterminate FIB-4: A 10–15 minute non-invasive scan measuring liver stiffness (kPa) and fat content (CAP score). Available across Australia at $150–$300. No radiation. No hospitalisation. Results available immediately.
- A liver stiffness below 8 kPa: reassuring — no significant fibrosis.
- A liver stiffness 8–13 kPa: moderate to significant fibrosis — warrants specialist review and active monitoring.
- A liver stiffness above 13 kPa: cirrhosis range — urgent specialist referral.
- Step 3 — Act on the result. For patients with F2–F3 fibrosis identified in the early detection pathway, treatment options now include semaglutide under the new TGA MASH indication, dietary and lifestyle intervention, and specialist-guided monitoring.
Patient guide · Reviewed May 2026
Early Detection vs Late Detection — The Clinical Difference
The difference between F2 and F4 at diagnosis can be a decade of undetected disease. Systematic early detection compresses that gap.
| Stage at Detection | Fibrosis Stage | Treatment Options | Prognosis |
|---|---|---|---|
| Early (asymptomatic screening) | F0–F2 | Lifestyle, semaglutide, monitoring | Excellent with intervention |
| Intermediate | F2–F3 | Semaglutide (TGA approved), specialist monitoring | Good with treatment |
| Late (symptomatic) | F3–F4 | Specialist management, cirrhosis monitoring | Variable — cirrhosis limits options |
| Very late | F4 + complications | Specialist management, transplant assessment | Serious |
The difference between F2 and F4 at diagnosis can be a decade of undetected disease. Systematic early detection compresses that gap.
Finding an Early Detection Clinic Near You
Liver elastography for early detection is available at clinics across Australia. A growing number accept self-referred patients — you do not always need a GP referral to attend.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
How is liver disease detected early?
The recommended Australian pathway is a FIB-4 score calculated from routine blood tests, followed by liver elastography (FibroScan or guided elastography) for patients in the indeterminate range. Both are non-invasive, accessible in primary care, and recommended in the MJA September 2025 consensus statement.
Can fatty liver disease be cured if caught early?
Simple steatosis (fat without significant inflammation) can be fully reversed with lifestyle changes including weight loss. MASH (inflammatory fatty liver) at F2–F3 fibrosis can be significantly improved with semaglutide under Australia's April 2026 TGA approval. Early detection — before cirrhosis develops — is the critical window.
What symptoms indicate early liver disease?
Usually none. This is the core challenge. Persistent fatigue is the most common early symptom but is non-specific. Most early MASLD is diagnosed incidentally through blood tests showing elevated liver enzymes. Systematic screening of at-risk populations is the only reliable early detection strategy.
How often should I be tested for liver disease?
If your FIB-4 is low risk (below 1.3), repeat in 3 years. If you are on a GLP-1 medication with metabolic risk factors, annual liver function tests are appropriate. If your elastography shows F2 or above, your specialist will advise the monitoring interval — typically annual.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or submit an appointment request and we will route you to the nearest available provider.